Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19

Krishan D. Chhiba,Gayatri B. Patel,Thanh Huyen T. Vu,Michael M. Chen,Amina Guo,Elizabeth Kudlaty,Quan Mai,Chen Yeh,Lutfiyya N. Muhammad,Kathleen E. Harris,Bruce S. Bochner,Leslie C. Grammer,Paul A. Greenberger,Ravi Kalhan,Fei Li Kuang,Carol A. Saltoun,Robert P. Schleimer,Whitney W. Stevens,Anju T. Peters
DOI: https://doi.org/10.1016/j.jaci.2020.06.010
IF: 14.29
2020-08-01
Journal of Allergy and Clinical Immunology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>The Centers for Disease Control and Prevention advises that patients with moderate-to-severe asthma belong to a high-risk group that is susceptible to severe COVID-19. However, the association between asthma and COVID-19 has not been well-established.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>The primary objective was to determine the prevalence of asthma among COVID-19 patients in a major U.S. health system. We assessed the clinical characteristics and comorbidities in asthmatic and non-asthmatic COVID-19 patients. We also determined the risk of hospitalization associated with asthma and/or inhaled corticosteroid use.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Medical records of patients with COVID-19 were searched by a computer algorithm (March 1–April 15, 2020), and chart review was used to validate the diagnosis of asthma and medications prescribed for asthma. All patients were PCR-confirmed COVID-19. Demographics and clinical features were characterized. Regression models were used to assess the associations between asthma and corticosteroid use and the risk of COVID-19-related hospitalization.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Of 1,526 patients identified with COVID-19, 220 (14%) were classified as having asthma. Asthma was not associated with an increased risk of hospitalization (RR of 0.96 [95%CI: 0.77-1.19]) after adjusting for age, sex, gender, and comorbidities. The ongoing use of ICS did not increase the risk of hospitalization in a similar adjusted model (RR of 1.39 [95%CI: 0.90-2.15]).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Despite a substantial prevalence of asthma in our COVID-19 cohort, asthma was not associated with an increased risk of hospitalization. Similarly, the use of ICS with or without systemic corticosteroids was not associated with COVID-19-related hospitalization.</p>
immunology,allergy
What problem does this paper attempt to address?